Presentation to feature overview of positive interim Phase 1 CMV vaccine data and preclinical Zika vaccine data demonstrating neutralizing antibody response
VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today announced that Adam Buckley, vice president of business development, will discuss VBI’s enveloped virus-like particle (eVLP) platform, highlighting data from two of the company’s vaccine programs, during a presentation at the World Vaccine Congress Europe held Oct. 10-12, 2017, in Barcelona.
During the presentation, Mr. Buckley will provide a synopsis of VBI’s eVLP technology, including an overview of the positive interim data from the Phase I clinical study of VBI’s cytomegalovirus (CMV) vaccine and new preclinical data on VBI-2501, the company’s bivalent Zika vaccine candidate, which demonstrated neutralizing antibody responses benchmarked to levels of naturally acquired Zika immunity.
- Event: The World Vaccine Congress Europe 2017
- Date: Thursday, October 12, 2017
- Time: 10:25 AM CET
- Location: The Crowne Plaza Hotel Barcelona, Fira Center, Barcelona
- Event Website: http://www.terrapinn.com/conference/world-vaccine-congress-europe/agenda.stm
CMV can cause serious disease in newborns when a mother is infected during pregnancy. Each year, approximately 5,000 U.S. infants will develop permanent problems due to CMV, which can include deafness, blindness, and developmental delays. CMV affects more live births than Down syndrome or fetal alcohol syndrome, making it a key public health priority and a strong candidate for recommended universal vaccination and reimbursement.
To learn more about CMV, visit: https://www.vbivaccines.com/cmv/
About Zika Virus
Zika is a flavivirus related to dengue, yellow fever, and West Nile. While the acute manifestations of Zika virus infection are typically mild, the disease has been associated with a number of neurological complications. There is scientific consensus that the Zika virus can cause congenital microcephaly, a condition where a child is born with a smaller than expected head due to abnormal brain development. Zika virus may also cause Guillain-Barrė syndrome (“GBS”), a disorder in which the body’s immune system attacks the nerves, leading to muscle weakness or, in severe cases, paralysis.
Zika is spread primarily through the bite of an infected Aedes species mosquito, but some evidence suggests that it also may be transmitted sexually or during childbirth. In February 2016, the World Health Organization (“WHO”) declared Zika a Public Health Emergency of International Concern (“PHEIC”), saying that the virus was “spreading explosively” in the Americas. There is currently no vaccine to prevent Zika infection.
To learn more about VBI’s Zika Vaccine Program, visit: https://www.vbivaccines.com/zika/